A large number of drugs are transferred out of medical insurance

In the last few months, a large number of medicines will be transferred out of medical insurance in many provinces
.

01 On January 1, next year, a large number of drugs will be transferred out of medical insurance

Guizhou (339)

On August 3, the Guizhou Medical Insurance Bureau and the Guizhou Department of Human Resources and Social Security issued the "Notice Regarding the Transfer of Some Medicines from the "Guizhou Province Basic Medical Insurance Work Injury Insurance and Maternity Insurance Drug List (2021)", stating:

1.
Starting from January 1, 2022, 339 drugs including sidiadine will be transferred out of the "Drug List"
.

Zhejiang (118)

On August 3, the Zhejiang Medical Insurance Bureau and the Zhejiang Human Resources and Social Security Bureau issued the "Notice on Transferring Some Medicines from the Zhejiang Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Lists" to require:

1.
Starting from January 1, 2022, 118 drugs including amoxicillin and dicloxacillin will be transferred out of the Zhejiang Provincial Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog
.

Sichuan (145)

On July 26, the Sichuan Medical Insurance Bureau issued the "Notice on Further Improving the Digestion of Class B Drugs in Our Province's Basic Medical Insurance, Work Injury Insurance and Maternity Insurance (Draft for Solicitation of Comments)", showing:

According to expert argumentation, the Sichuan Provincial Medical Insurance Bureau has decided to transfer 145 drugs such as boron ointment from the payment scope of Sichuan Basic Medical Insurance, Work Injury Insurance and Maternity Insurance from January 1, 2022
.

Jiangsu (156)

On July 14, the Jiangsu Provincial Medical Insurance Bureau issued the "Notice of the Jiangsu Provincial Department of Human Resources and Social Security on the Publication of the Second Batch of Digestible Lists of Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drugs List of Provincial Supplementary Drugs", showing:

Provincial-level medical insurance agencies shall maintain the information of the Jiangsu Provincial Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog Database in a timely manner, and call out all the varieties under the generic name of the second batch of digestive drugs involved
.

At the same time, Jiangsu Province announced that starting from January 1, 2022, the costs of all imported medicines will no longer be included in the payment scope of Jiangsu Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Fund
.

Chongqing

According to the arrangement of the Chongqing Medical Insurance Bureau, the digestion time schedule for the local medical insurance products in Chongqing is as follows:

Digest medicines in the first year, and stop medical insurance reimbursement from January 1, 2021;

Digest the medicine in the second year, and stop medical insurance reimbursement from January 1, 2022;

In the third year, the reimbursement of medicines will be discontinued from July 1, 2022
.

The second year digestive drugs are as follows:

Ampicillin toxin probenecid (oral regular-release dosage form, the drug has been renamed "ampicillin probenecid"), flucloxacillin (injection), cefazolin pentahydrate (injection), cefmenoxime (injection), ceftriax Sontazobactam (injection), ceftiziaride (injection), roxithromycin (sustained-release and controlled-release dosage form), andrographolate (injection), chlorzoxazone (oral constant-release dosage form), gaaconitine (injection) ), compound amino acids (8-11) (oral constant-release dosage form), deoxynucleotides (injection), compound amino acids (15) dipeptide (2) (injection), long-chain fat emulsion (OO) (injection), card Bacterial polysaccharide nucleic acid (injection), pidotimod (oral constant-release dosage form), placental polypeptide (injection), paclitaxel liposome (injection), recombinant human tumor necrosis factor (injection), vinblastine (sustained release control) Release dosage form), acutinase (injection), gluten red (injection), meclofenoxate (injection), acetyl gastrodin (oral regular-release dosage form), ambroxol (slow-release controlled-release dosage form), compound codeine (Oral liquid), Cisapride (oral regular-release dosage form), oxymatrine (oral regular-release dosage form), ornithine aspartate (granules), Shenxiong glucose (injection), coenzyme Q10 (oral regular-release dosage form) Release dosage form), L-carnitine (oral liquid), mannan peptide (injection), sodium fructose diphosphate (oral liquid), low molecular weight dextran amino acid (injection), compound electrolyte (injection), sodium potassium magnesium calcium Glucose (injection), amiodarone (eye drops), three-dimensional nystatin (suppository), Qingchang laxative capsules, Qinlian tablets (granules, capsules), monkey earring anti-inflammatory tablets, Phyllanthus capsules (tablets), Shalian Hewei Capsules, Yemazhuan Syrup, Anti-Brain Failure Capsules, Yinaoxin Granules, Wuzi Yanzong Oral Liquid (Pills, Tablets, Soft Capsules), Schisandra Syrup (Capsules, Tablets, Granules), Compound Fufangteng Mixture ( Capsules), Fufang Dahongpao Zhixue Capsules, Xuekang Oral Liquid (granules), Zhixuebao Granules, Xinmailong Injection, Xuefu Zhuyu Soft Capsules, Danshen for Injection, Safflower Yellow Pigment for Injection, Yixintong Tablets ( Capsules), Haidan Capsules, St.
John's Wort Extract Tablets, Chenxiang Huaqi Pills (Capsules), Saw Palmetto Fruit Extract Soft Capsules, Jiangzhi Tongluo Soft Capsules, Xiaoshi Lidan Capsules, Musk Shuhuoling, Chansu Injection, Jinsang Liyan Pills, Zhenhuang Pills, Dusheng Huoxue Tablets, Breviscapine Dispersible Tablets, Shugan Yipi Granules, Entacapone Didopa Tablets (Ⅱ) (tablets, Beijing Novartis Pharmaceutical Co.
, Ltd.
Company), pioglitazone and metformin tablets (tablets, Hangzhou Sino-American Huadong Pharmaceutical Co.
, Ltd.
, Jiangsu Deyuan Pharmaceutical Co.
, Ltd.
), Latan Timol eye drops (eye drops, PfizerManufacturing Belgium NV), mixed sugar and electrolyte injection (injection, Jiangsu Zhengda Fenghai Pharmaceutical Co.
, Ltd.
), perindopril indapamide tablets (tablet, Servier (Tianjin) Pharmaceutical Co.
, Ltd.
), fatty milk amino acid ( 18) Injection (injection, Sichuan Kelun Pharmaceutical Co.
, Ltd.
), estradiol/estradiol dydrogesterone tablets composite packaging (tablets, Abbott Biologicals BV), oxaliplatin and mannitol injection (injections) , Sichuan Meida Kangjiale Pharmaceutical Co.
, Ltd.
, Chenxin Pharmaceutical Co.
, Ltd.
), fat-soluble vitamin for injection (Ⅱ)/water-soluble vitamin for injection combined packaging (injection, Chengdu Tiantaishan Pharmaceutical Co.
, Ltd.
, Hebei Zhitong Biopharmaceutical Co.
, Ltd.
), Candihydrothiazide tablets (tablets, Jiangsu Deyuan Pharmaceutical Co.
, Ltd.
), compound vitamins for injection (3) (injections, Liaoning Haisco Pharmaceutical Co.
, Ltd.
), omeprazole sodium bicarbonate capsules ( Capsules, Xiamen Encheng Pharmaceutical Co.
, Ltd.
), Diclofenac Sodium Lidocaine for Injection (injection (freeze-dried powder injection), Beijing Sihuan Kebao Pharmaceutical Co.
, Ltd.
), Xingxiong Sodium Chloride Injection (injection, Honghe Pharmaceutical ( China) Co.
, Ltd.
), multiple oil and fat emulsion injection (C6-24) (injection, Fresenius Kabi Austria GmbH), compound brain peptide ganglioside injection (injection, Jilin Buchang Pharmaceutical Co.
, Ltd.
, the manufacturer changed its name to Jilin Tiancheng Pharmaceutical Co.
, Ltd.
), compound treotide injection (injection, Jilin Buchang Pharmaceutical Co.
, Ltd.
, the manufacturer changed its name to Jilin Tiancheng Pharmaceutical Co.
, Ltd.
), travothiamol eye drops (eye drops, sa ALCON-COUVREUR nv), ambroxol oral solution (oral solution, Beijing Hanmei Pharmaceutical Co.
, Ltd.
), 12 multivitamins for injection (injection, the drug has been renamed "multivitamins for injection (12)", Shanxi Pude Pharmaceutical Co.
, Ltd.
Co.
, Ltd.
), compound diclofenac sodium injection (injection, Guangzhou Baiyunshan Mingxing Pharmaceutical Co.
, Ltd.
), alendronate vitamin D3 tablets (Ⅱ) (tablets, Hangzhou Merck Pharmaceutical Co.
, Ltd.
), clindamycin glucose injection Solution (injection), ambroxol glucose injection (injection), granisetron hydrochloride glucose injection (injection), doxofylline glucose injection (injection), ozagrel sodium glucose injection (injection), hydrochloric acid Bromhexine glucose injection (injection), clindamycin sodium chloride injection (injection), ambroxol hydrochloride and sodium chloride injection (injection), famotidine sodium chloride injection (injection), hydrochloric acid Tropisetron sodium chloride injection (injection), potassium chloride and sodium chloride injection (injection), nicardipine hydrochloride and sodium chloride injection (injection), ozagrel sodium and sodium chloride injection (injection) , Piracetam Sodium Chloride Injection (Injection), Ofloxacin Sodium Chloride Injection (Injection), Betahistine Hydrochloride Sodium Chloride Injection (Injection), Morpholinidazole Sodium Chloride Injection (injection)

02 The transfer of local medical insurance will meet the final deadline

According to Cyberlan’s earlier analysis, the intensive period of the last local medical insurance transfer was January 1 at the beginning of this year—Jiangsu (111), Shaanxi (63), Qinghai (129), Henan (320) Some medicines in Chongqing, Chongqing and other places will no longer be reimbursed from January 1, 2021
.

Looking at the notices of medical insurance transfers from many provinces, before that, July 1, 2020, September 1, 2020, October 1, 2020, January 1, 2021, July 1, 2021, and August 2021.
January 1st is the main time limit for the suspension of reimbursement for some local medical insurance products in many provinces
.

Cyberlane's combing this time found that the new wave of call-out climax is January 1, 2022
.

According to the schedule of related parties, the timetable for the transfer of local supplementary products to the medical insurance is as follows: 1.
The drugs under the key monitoring list are first removed from the medical insurance list; 2.
The remaining local supplementary varieties will be cleared within three years in principle, and the proportions of the three-year cleared varieties are respectively It is 40%, 40%, 20%
.

According to incomplete statistics, as of now, more than 20 provinces, including Yunnan, Hunan, Jilin, Tianjin, Hebei, Anhui, Tibet, Sichuan, and Henan, have implemented local supplementary catalogue transfer policies
.

According to Cyberlan’s previous understanding, according to the "Notice on Doing a Good Job in Basic Medical Security for Urban and Rural Residents in 2021" issued by the National Medical Insurance Administration, the Ministry of Finance, and the State Administration of Taxation, all provinces (autonomous regions and municipalities) must complete the work before the end of June 2021.
The second batch of 40% supplementary variety digestion work
.

In other words, as of now, as planned, 80% of the digestion of supplementary products for local medical insurance has been completed
.

The key points of the 2021 medical insurance work circulated a few days ago are clear: do a good job in the cleaning and digestion of the provincial supplementary drug catalog to ensure that the drug catalog is basically unified nationwide by 2022

According to the requirements of relevant documents, all regions need to clean up the varieties that do not meet the requirements of the "Interim Measures for the Administration of Basic Medical Insurance Medications" as required to promote the basic unification of the scope of medication

All localities should strictly implement the "Drug Catalogue", and must not make their own catalogues or use flexible methods to add drugs in the catalogue, nor can they adjust the limited payment scope of the drugs in the catalogue by themselves

With the completion of the clean-up of local medical insurance supplements, the annual regular adjustment of the national medical insurance catalog has become a more important window of opportunity for pharmaceutical companies

However, it is worth noting that even in the National Medical Insurance Catalogue, the withdrawal and price reduction of drugs are also occurring

The work plan for the adjustment of the medical insurance catalog in the past two years has stipulated that the medicines that have been cancelled, the risks are greater than the benefits, and are included in the negative list by the relevant departments will be transferred out of the national medical insurance

At the same time, renegotiations for renewed drugs, increased medical insurance payment restrictions for some varieties, and negotiated price cuts for some drugs in the catalog to make room for drugs with more clinical value and better clinical benefits

Statistics show that China’s medical insurance catalogue has been growing in terms of the total amount of medicines.

Which drugs have the opportunity to obtain medical insurance reimbursement qualifications is undoubtedly the most important issue for companies in the industry every year

Attachment: Many provinces transferred out the list of medical insurance drugs on January 1, 2022

Guizhou (339)

Zhejiang (118)

Sichuan (145)

Jiangsu (156)